Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.70 |
| ▸ | ATM | Q13315 | 1/20 | 0.60 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | BRD4 | O60885 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3230797 | 0.89 | ATM (0.66) | MAPTATMPABPC1ALOX15TDP1 | |
| SCHEMBL3227925 | 0.87 | MTNR1A (0.69) | MAPTTDP1KMT2AMEN1LMNA | |
| SCHEMBL3384994 | 0.83 | MAPT (0.68) | MAPTATMPABPC1ALOX15TDP1 | |
| SCHEMBL3382735 | 0.83 | ATM (0.63) | MAPTATMPABPC1ALOX15TDP1 | |
| SCHEMBL15835701 | 0.83 | KDM4E (0.58) | MAPTPABPC1ALOX15KMT2AMEN1 | |
| SCHEMBL14334118 | 0.83 | KDM4E (0.58) | MAPTPABPC1ALOX15KMT2AMEN1 | |
| SCHEMBL14334116 | 0.83 | KDM4E (0.58) | MAPTPABPC1ALOX15KMT2AMEN1 | |
| SCHEMBL7863760 | 0.82 | MAPT (0.72) | MAPTATMPABPC1ALOX15TDP1 | |
| SCHEMBL3385338 | 0.82 | MEN1 (0.61) | MAPTTDP1KMT2AMEN1 | |
| SCHEMBL3605297 | 0.82 | ATM (0.65) | MAPTATMPABPC1ALOX15TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029598-A1 | Extended Benzamide Derivatives as Modulators of the EP2 Receptor | BAYER SCHERING PHARMA AG (DE) | 2010-02-04 | — | — | US | claimed |
| EP-2149551-A1 | N-(indol-3-ylalkyl)-(hetero)arylamid derivatives as modulators of EP2 receptors | Bayer Schering Pharma AG (DE) | 2010-02-03 | — | — | EP | claimed |
| US-20100029598-A1 | Extended Benzamide Derivatives as Modulators of the EP2 Receptor | BAYER SCHERING PHARMA AG (DE) | 2010-02-04 | — | — | US | disclosed |
| EP-2149551-A1 | N-(indol-3-ylalkyl)-(hetero)arylamid derivatives as modulators of EP2 receptors | Bayer Schering Pharma AG (DE) | 2010-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029598-A1 | Extended Benzamide Derivatives as Modulators of the EP2 Receptor | PTGER2, PTGER1, PTGDR2 | MAPT 4374/4885ATM 4060/4885PABPC1 3808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.